Welcome to follow Kelleying Pharmaceutical News
On September 21, 2022, Abpro announced the establishment of a strategic partnership with Celltrion, combining Abpro's Diversimmune and Multimab platforms with Celltrion's experience in biopharmaceutical development to promote the development of ABP 102. ABP 102 is a T cell bonding agent used to treat HER2+ breast cancer, gastric cancer , and pancreatic cancer . According to the agreement, Abpro will receive up to US$1.75 billion in payments from Celltrion, including equity investment, development and commercial milestone payments and global profit commissions; after Abpro completes in vitro trials, Celltrion will be responsible for the development of ABP 102 and owns the global commercialization rights of the product.
Abpro
Abpro is a clinical stage biotechnology company based in Woburn, Massachusetts, dedicated to developing next-generation antibody therapies to improve the lives of patients with severe and life-threatening diseases.
Among them, the DiversImmune platform has been successfully used to generate monoclonal antibody therapies targeting 300 traditional difficult targets. The platform combines nanoimmunology, next-generation sequencing, advanced engineering and bioinformatics to create monoclonal antibody therapies against traditional difficult targets.
MultiMab platform uses two "arms" of dual-targeting antibodies or antibodies to capture tumor cells, allowing antibodies to bind simultaneously to tumor-specific antigen and cytotoxic T cells to kill tumor cells. T cells destroy tumor cells by using their own innate immune response to eliminate foreign cells. By including two tumor antigen binding sites, these molecules have enhanced connectivity compared to molecules with only a single binding site.
In addition, the company is building a T cell adapter pipeline based on the tetravalent bispecific (TetraBi) form, in which the representative drug ABP-100 adopts the TetraBi form, which has the following advantages compared with other biantiform and T-cell-based treatment methods: (1) Bivalent binding to tumor cells enhances efficacy; (2) Monovalent binding to CD3 enhances safety; (3) Fc region can be better administered; (4) Fc controls immune effect function; (5) Lower immunogenicity ; (6) Simplify manufacturing methods.
Currently, the company has a series of pipelines for the treatment of cancer, ophthalmology, autoimmune, infectious diseases and other fields.
About Celltrion
Celltrion is a biopharmaceutical company in South Korea and is a global leader in the field of biosimilars. The company has achieved great success in many unknown areas and plans to continue to grow into a global biopharmaceutical company that develops small molecule drugs and new businesses in a unique way.
About the dual anti-
catamomals can bind 2 different targets at the same time, where one directly binds to the specific antigen on the cancer cells, and on the other side activates T cells in the patient's autoimmune system and makes it closer to the cancer cells to kill it. Due to its functional improvements, dual antibody has a more complex structure than monoclonal antibody. Its clinical value of is:
1) Compared with the combination of two monoclonal antibodies, the potential safety optimization, efficacy optimization, and the cost reduction after the technology is mature.
2) Through the new function - bridging , you can directly recruit immune cells , which can play a stronger killing role. What is to be developed is also the function of crossing the blood-brain barrier.
3) Through the new function - combining with 2 targets on a cell, it can play a dual signal blocking role and prevent the activation of bypass signals.
dual antibody vs. other antibody drugs
At present, 8 dual antibody has been approved for marketing around the world. The specific information statistics are as follows:
According to Frost Sullivan's data, the global monoclonal antibody scale in 2020 was US$174.9 billion, and the industry growth rate is expected to be 4.2% from 2024 to 2030. The market size of the dual-anti-anti-anti-anti-industry industry in 2020 is US$2.5 billion, and the industry growth rate is expected to be 29.3% from 2024 to 2030. The growth rate of the dual-antibody industry is higher than that of monoclonal antibodies.
Global dual antibody/monoanti antibody drug market size and growth rate
(unit: billion US dollars)
It is expected that China's dual antibody market will reach US$10.8 billion in 2030, with a growth rate of 54.3% from 2024 to 2030; the monotonymia market size is US$57.9 billion, with a growth rate of 16.7% from 2024 to 2030. The growth rate of the dual-antibody industry is higher than that of monoclonal antibodies.
China's dual-anti-mono-anti-anti-anti-drug drug market size and growth rate
(unit: billion US dollars)
